Nanomedicine News

RSS

Two ‘Parent’ Nanoparticles Method Holds Promise for More Efficient Medical Treatments

More efficient medical treatments could be developed thanks to a new method for triggering the rearrangement of chemical particles.

19 Jan 2015

Tumor Microenvironment Could Play a Big Role in Nanoparticle-Based Cancer Therapy

Nanoparticle drugs--tiny containers packed with medicine and with the potential to be shipped straight to tumors--were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall survival rates for cancer patients very much. Scientists at the University of North Carolina at Chapel Hill now think that failure may have less to do with the drugs and tumors than it does the tumor's immediate surroundings.

14 Jan 2015

New Data on Dicerna’s DsiRNA Therapeutics Targeting MYC, β-Catenin Oncogenes Presented at AACR Meeting

Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and â-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC).

13 Jan 2015

Published Data Suggests Clinical Benefits from Celator CPX-351 in First Relapse AML Patients

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society.

13 Jan 2015

Sorrento Commences Dosing in TRIal Establishing Bioequivalence Between Cynviloq™ and Albumin-Bound Paclitaxel

Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA™ (TRIal establishing bioequivalence [BE] between Cynviloq™ and Albumin-bound paclitaxel*) registrational trial have been dosed. Sorrento intends to continue enrolling all qualified patients in the current screening process and anticipates having the "last patient in" by the end of January.

13 Jan 2015

Precision NanoSystems and Arcturus Therapeutics Enter Partnership to Produce RNA Medicines

Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines.

12 Jan 2015

Tekmira and OnCore to Merge and Create New Global HBV Company

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, Inc., a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, announced today that they have agreed to merge to create a new leading global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

12 Jan 2015

Sangamo BioSciences In-Licenses Nanoparticle Technology for Systemic mRNA Delivery of ZFNs

Sangamo BioSciences, Inc. announced that the company has in-licensed nanoparticle technology to enable systemic messenger RNA (mRNA) delivery of Sangamo's proprietary zinc finger nucleases (ZFNs). mRNA delivery of ZFNs is being used in the development of the next generation of Sangamo's ZFP Therapeutics®.

9 Jan 2015

Major Research Project Receives Grant to Develop Nanoparticle-Based Cancer Treatment

Traditional cancer treatments like radiotherapy and chemotherapy have significant side effects, as they not only affect the cancer tumours, but also the healthy parts of the body. A major new research project will work to develop a treatment that only affects the tumours locally.

8 Jan 2015

NanoViricides Acquires cGMP-Compliant Manufacturing and R&D Facility from Inno-Haven

NanoViricides, Inc., has completed the purchase of the state of the art cGMP-compliant Manufacturing and R&D facility located in Shelton, Connecticut, from Inno-Haven, LLC.

From NanoViricides, Inc 8 Jan 2015

Nanomedicine News

Two ‘Parent’ Nanoparticles Method Holds Promise for More Efficient Medical Treatments

Tumor Microenvironment Could Play a Big Role in Nanoparticle-Based Cancer Therapy

New Data on Dicerna’s DsiRNA Therapeutics Targeting MYC, β-Catenin Oncogenes Presented at AACR Meeting

Published Data Suggests Clinical Benefits from Celator CPX-351 in First Relapse AML Patients

Sorrento Commences Dosing in TRIal Establishing Bioequivalence Between Cynviloq™ and Albumin-Bound Paclitaxel

Precision NanoSystems and Arcturus Therapeutics Enter Partnership to Produce RNA Medicines

Tekmira and OnCore to Merge and Create New Global HBV Company

Sangamo BioSciences In-Licenses Nanoparticle Technology for Systemic mRNA Delivery of ZFNs

Major Research Project Receives Grant to Develop Nanoparticle-Based Cancer Treatment

NanoViricides Acquires cGMP-Compliant Manufacturing and R&D Facility from Inno-Haven

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Gold Nanoparticles to Restore Vision in Retinal Disorders

Levidian and Zentek Seek to Establish Graphene-Integrated Filter Manufacturing Facility in the Middle East to Advance Cleaner, Safer Air

Scalable Method for Porous Graphene Membranes for CO2 Capture

Biochar-Modified Titanium Dioxide Nanocomposites for Enhanced Water Treatment

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting